Peter J. Graham Net Worth

The estimated Net Worth of Peter J Graham is at least $3.91 Million dollars as of 17 February 2021. Mr Graham owns over 45,000 units of Antares Pharma Inc stock worth over $3,272,481 and over the last 19 years he sold ATRS stock worth over $0. In addition, he makes $634,481 as Exec. VP of HR, Gen. Counsel und Chief Compliance Officer & Corp. Sec. at Antares Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Graham ATRS stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Antares Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of ATRS stock worth $50,400 on 17 February 2021.

The largest trade he's ever made was exercising 45,000 units of Antares Pharma Inc stock on 17 February 2021 worth over $50,400. On average, Mr trades about 2,321 units every 64 days since 2006. As of 17 February 2021 he still owns at least 585,417 units of Antares Pharma Inc stock.

You can see the complete history of Mr Graham stock trades at the bottom of the page.

Mr. Peter J. Graham biography

Peter J. Graham is the Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. at Antares Pharma Inc.

What is the salary of Mr Graham?

As the Exec. VP of HR, Gen. Counsel und Chief Compliance Officer & Corp. Sec. of Antares Pharma Inc, the total compensation of Mr Graham at Antares Pharma Inc is $634,481. There are 2 executives at Antares Pharma Inc getting paid more, with Robert F. Apple having the highest compensation of $1,003,646.

How old is Mr Graham?

Mr Graham is 54, he's been the Exec. VP of HR, Gen. Counsel und Chief Compliance Officer & Corp. Sec. of Antares Pharma Inc since . There are 4 older and no younger executives at Antares Pharma Inc. The oldest executive at Antares Pharma Inc is Dr. Peter Sadowski, 73, who is the Sr. VP of Technology Portfolio & Intellectual Property.

What's Mr Graham's mailing address?

Peter's mailing address filed with the SEC is C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300, EWING, NJ, 08628.

Insiders trading at Antares Pharma Inc

Over the last 12 years, insiders at Antares Pharma Inc have traded over $29,755,747 worth of Antares Pharma Inc stock and bought 910,400 units worth $1,278,090 . The most active insiders traders include James E Deerfield Mgmt L.P...., James E Deerfield Mgmt L.P.... und Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of $751,296. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth $429,000.

What does Antares Pharma Inc do?

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Complete history of Mr Graham stock trades at Angiodynamic Inc und Antares Pharma Inc

Antares Pharma Inc executives and stock owners

Antares Pharma Inc executives and other stock owners filed with the SEC include:

• Robert F. Apple,
  CEO, Pres & Director
• Fred M. Powell,
  Exec. VP & CFO
• Peter J. Graham,
  Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Greg Defilippis,
  Sr. VP of Device Bus. & Alliances
• Dr. Jonathan S. Jaffe,
  Interim EVP, Pharmaceutical R&D and Chief Medical Officer
• Dr. Peter Sadowski,
  Sr. VP of Technology Portfolio & Intellectual Property
• Edward Tykot,
  Sr. VP of Corp. Bus. Devel.
• Tram Bui,
  VP of Corp. Communications & Investor Relations
• Keith Muckenhirn,
  Principal Accounting Officer, VP of Fin. & Corp. Controller
• Patrick Madsen,
  Sr. VP of Operations
• Anton Gueth,
  Director
• Robert P Jr Roche,
  Director
• Thomas J Garrity,
  Director
• Fred M Powell,
  Executive Vice President & CFO
• Leonard S Jacob,
  Director
• Marvin Samson,
  Director
• James E Fickenscher,
  Senior Vice President & CFO
• James E Deerfield Mgmt L.P....,
  
• Jacques Gonella,
  Director
• Peter J Graham,
  See Remarks
• James Patrick Tursi,
  EVP, Chief Medical Officer
• Peter Greenleaf,
  Director
• Karen L. Smith,
  Director
• James E Deerfield Mgmt L.P....,
  
• Kaushik J Dave,
  Executive Vice President
• Jennifer Evans Stacey,
  SVP, General Counsel & Secty
• James E Deerfield Mgmt L.P....,
  
• Paul K Wotton,
  President and CEO
• Eamonn P Hobbs,
  Director
• Peter C Richardson,
  See Remarks
• Carmen B Volkart,
  Director
• Robert F Apple,
  President and CEO